A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1
Public ClinicalTrials.gov record NCT00239148. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Effects of Repeated Subcutaneous Doses of E1 in Combination With G1 in Type 1 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine whether E1 and G1 are safe and effective in the treatment of type 1 diabetes. Type 1 diabetes is an autoimmune disease, in which the immune system attacks pancreatic beta cells. These cells produce insulin, which regulates blood glucose. The mainstay of current treatment for type 1 diabetes is dietary control and daily parenteral administration of insulin. Recent diabetes research has increasingly focused on pancreatic islet cell replacement, either by islet cell transplantation or by endogenous regeneration of islet cells. During fetal development, islet precursor cells proliferate and differentiate into mature beta cells capable of producing insulin. This process is known as islet cell neogenesis. Islet cell neogenesis normally ceases around birth, however, the adult pancreas still retains significant potential for islet regeneration, as shown by tissue repair following pancreatic injury. Pre-clinical studies have shown that E1 and G1 can re-establish islet cell neogenesis and increase pancreatic insulin production in diabetic animal models. It is therefore postulated that treatment with E1 and G1 may produce islet cell regeneration in type 1 diabetic patients.
Study identification
- NCT ID
- NCT00239148
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2005
- Primary completion
- Not listed
- Completion
- Nov 30, 2006
- Last update posted
- Oct 17, 2019
2005 – 2006
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group | Anniston | Alabama | 36207 | — |
| Diablo Clinical Research | Walnut Creek | California | 94598 | — |
| Diabetes - Endocrinology Center of West New York | Buffalo | New York | 14209 | — |
| Highgate Specialty Center | Durham | North Carolina | 27713 | — |
| Diabetes and Glandular Disease Research Associates | San Antonio | Texas | 78229-4801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Type 1 Diabetes trials
Other public records listing Type 1 Diabetes. Sorted by last update posted; newest first. Not a recommendation.
- NCT07793097: Can Mindfulness and Virtual Reality Reduce Stress in Young Adults With Type 1 Diabetes? Not yet recruiting
- NCT07413874: Telehealth Music Therapy for Adults With Endocrine Disorder and Depression Recruiting
- NCT06654713: Commercial or Open Source Closed Loop Impact on Pregnancy Study Recruiting
- NCT06160934: The T1D Parent Check-In: A Preventative Intervention Active, not recruiting
- NCT07706803: Screening For Social Determinants Of Health In Routine Diabetes Care Not yet recruiting
- NCT07676565: Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00239148, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2019 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00239148 live on ClinicalTrials.gov.